Tiny study hopes to unlock muscle secrets in overweight men
NCT ID NCT07421024
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will give 10 overweight men a daily pill called ATR-258 for 8 weeks to see how it changes signaling pathways in their muscles. Researchers will take small muscle samples and measure blood sugar control and body composition. The goal is to understand the biology, not to treat or cure obesity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATR-258 (a drug that targets beta-2 receptors in muscle)
What this could lead to
If successful, this study could reveal new ways to improve muscle metabolism and glucose handling in people with overweight or obesity.
What could go wrong
This is a small, early-phase mechanistic study with only 10 participants. It is designed to understand biology, not to test a treatment, so results may not lead to any direct health benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Copenhagen, August Krogh Section for Human & Molecular Physiology
Copenhagen, 2100, Denmark
Contact Email: •••••@•••••